Latest news Latest news Latest news

Latest news

Portfolio

AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma

20/07/2022 - 08:20

Portfolio

Gimv transfers stake in the Eurocept group - active in "Hospital-at-home" services, outpatient clinics and specialty pharmaceuticals - to its founder

13/07/2022 - 07:30

Portfolio

Gimv, Lenaerts/LVR and ABN Climatization lay the foundation of a leading group of installation companies

12/07/2022 - 07:30

Corporate

Report of the Annual and Special General Shareholders’ Meeting - Approval of a gross dividend of EUR 2.60 per share in the form of an optional dividend

29/06/2022 - 17:45

Corporate

Gimv - Modalités du dividende optionnel Apport du droit au dividende net en échange de la souscription d'une nouvelle action à 45,50 euros ou 25 droits au dividende relatifs à l’exercice 2021/2022

29/06/2022 - 07:30

Portfolio

Gimv strengthens its position in life sciences venture capital with the creation of a new dedicated platform

15/06/2022 - 07:30

ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline

14/06/2022 - 13:55

Portfolio

Gimv takes a significant interest in Picot, an industrial group active in the production of gates & fencing and provider of fencing solutions

09/06/2022 - 07:30

Portfolio

Gimv co-leads CHF 71M (USD 74M) Series B financing in ImmunOs Therapeutics to develop novel therapies in oncology and autoimmune disease.

07/06/2022 - 07:30

Corporate

Convocation of the annual general meeting of Gimv on June 29th, 2022

25/05/2022 - 17:00

Portfolio

Gimv further invests in industrial automation and becomes majority owner of workpiece carrier specialist Variotech

24/05/2022 - 07:30

Corporate

Impressive growth performance of our companies leads to strong result

19/05/2022 - 06:58

Contact information

Investor Relations Investor Relations Investor Relations

Investor Relations

Do you have any questions or require more information? Please contact us.